Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/16/2025

Management of Aspirin Therapy Before EGD in Elderly Patients with CAD and Suspected GI Bleed

Risk Assessment and Decision Algorithm

  • The American Heart Association recommends that aspirin be temporarily held for 3-5 days prior to the EGD procedure in patients with suspected gastritis or mild gastrointestinal bleeding, despite their history of CAD, to minimize bleeding risk 1, 2
  • Temporary interruption of aspirin is appropriate when active bleeding is suspected, as the risk of bleeding outweighs the short-term cardiovascular risk of discontinuing aspirin 1, 2
  • The American College of Cardiology suggests that patients with a remote history of CABG are at lower risk for acute cardiovascular events during brief aspirin interruption compared to patients with recent interventions 1, 3

Timing of Aspirin Discontinuation

  • The American Heart Association recommends discontinuing aspirin for at least 3-5 days before elective procedures with bleeding risk to allow for adequate reduction in bleeding risk while minimizing cardiovascular vulnerability 4

Resumption of Aspirin Therapy

  • The American College of Cardiology recommends resuming aspirin within 5 days of the last dose after successful endoscopic therapy and source control to minimize cardiovascular risk 2
  • Early reintroduction of aspirin (within 24-72 hours after EGD) is appropriate if no high-risk bleeding stigmata are found and hemostasis is achieved 2

Special Considerations

  • The American Heart Association suggests that aspirin may need to be held longer in patients with significant bleeding, with consideration for PPI co-therapy upon resumption 2
  • The American College of Cardiology recommends initiating PPI therapy after EGD with successful source control to reduce recurrent bleeding risk 2
  • The American Heart Association suggests resuming aspirin at the 81mg dose (preferred over higher doses) once hemostasis is confirmed to minimize bleeding risk while maintaining cardiovascular benefit 1, 5

Common Pitfalls to Avoid

  • The American College of Cardiology warns against continuing aspirin despite active GI bleeding, which can worsen bleeding and complicate endoscopic visualization 2
  • The American Heart Association advises against discontinuing aspirin for unnecessarily long periods (>7 days), which increases cardiovascular risk 4
  • The American College of Cardiology recommends against failing to resume aspirin therapy after successful bleeding source control, especially in patients with coronary stents or prior CABG 1
  • The American Heart Association suggests avoiding higher maintenance doses of aspirin (>81mg) upon resumption, which increases bleeding risk without additional cardiovascular benefit 1, 5